Core--Molecular Laboratory

核心--分子实验室

• 批准号: 7117726
• 负责人: BARBARA A ZEHNBAUER
• 金额: $ 5.55万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/7117726
• 关键词: artificial chromosomes; biomedical facility; molecular oncology; neoplasm /cancer; neoplasm /cancer genetics; nucleic acid sequence; polymerase chain reaction; southern blotting

The Molecular Core Laboratory (MCL) of the $iteman Cancer Center is a shared resource facility that provides molecular pathology services to both basic research and clinical research studies. The mission of the MCL is to rapidly translate basic research observations to new diagnostic and/or prognostic clinical molecular tests. The MCL works with researchers to develop and implement molecular biology assays to analyze mutations and aberrant gone expression in human malignancies, The methods utilized in the MCL range from the routine (genomic Southern analysis, PCR screening, DNA sequencing) to project-specific techniques (BAC probes, protein truncation test, telomere length). New projects frequently require adaptation and optimization of new or existing procedures in a project-specific focused approach. The Investigators consult with the MCL director to define goals of the research and molecular tesl.ing options that best serve the project. This individualized attention and professional expertise affords a substantial economy of service from this shared resource to Cancer Center members and other Washington University School of Medicine researchers. With the rapid advancement of the understanding of the genetic basis of common neoplasias, the availability of expert research support for clinical studies will serve to expedite assessment of genetic markers and to rapidly translate research findings to clinical tools. The MCL is also a resource of key equipment for molecular genetic research available for supervised shared use. Molecular test development and fees are configured with the investigator per collaborative project with a chargeback system to reimburse the MCL for project-specific reagents and services. Many research projects supported by the MCL have resulted in translation of the findings to new clinical lab tests for patients at SCC and referred from other US centers. Test validation to clinical application is uniquely achieved through the interface with the personnel and facilities of the adjoining Clinical Molecular Diagnostic Laboratory facility [CAP & CLIA-certified], also directed by Barbara A. Zehnbauer, Ph.D.

$iteman癌症中心的分子核心实验室（MCL）是一个共享资源设施，为基础研究和临床研究提供分子病理学服务。MCL的使命是将基础研究观察结果快速转化为新的诊断和/或预后临床分子检测。MCL与研究人员合作开发和实施分子生物学检测，以分析人类恶性肿瘤中的突变和异常gone表达，MCL中使用的方法范围从常规（基因组Southern分析，PCR筛选，DNA测序）到项目特定技术（BAC探针，蛋白质截短测试，端粒长度）。新项目经常需要采用针对具体项目的方法调整和优化新的或现有的程序。研究者与MCL主任协商，以确定研究目标和最适合该项目的分子选择。tesl.ing这种个性化的关注和专业知识为癌症中心成员和其他华盛顿大学医学院的研究人员提供了大量的服务经济。随着对常见肿瘤的遗传基础的理解的迅速发展，为临床研究提供专家研究支持将有助于加快遗传标记的评估，并将研究结果快速转化为临床工具。MCL也是分子遗传学研究的关键设备资源，可供监督共享使用。每个合作项目的分子检测开发和费用由研究者配置，并通过收费系统报销MCL的项目特定试剂和服务。许多研究项目得到了 MCL已将发现转化为SCC患者的新临床实验室检查，并从其他美国中心转介。临床应用的测试验证是通过与相邻的临床分子诊断实验室设施[CAP & CLIA认证]的人员和设施的接口唯一实现的，也由Barbara A. Zehnbauer博士